Monopar TherapeuticsMNPR +9.14%35 Current Ratio is 56.04 as of Mar. 2026, which is 210% above its 10-year median of 18.10. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,417 Biotechnology companies, Monopar Therapeutics ranks better than 98.73% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Monopar Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 56.04.
Monopar Therapeutics has a current ratio of 56.04. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Monopar Therapeutics's Current Ratio or its related term are showing as below:
MNPR'
s Current Ratio Range Over the Past 10 Years
Min: 4.08 Med: 18.1 Max: 56.09
Current: 56.04
During the past 10 years, Monopar Therapeutics's highest Current Ratio was 56.09. The lowest was 4.08. And the median was 18.10.
MNPR's Current Ratio is ranked better than 98.73% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs MNPR: 56.04
Monopar Therapeutics (NAS:MNPR) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Monopar Therapeutics Current Ratio Related Terms
Monopar Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Monopar Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MNPR vs IPSC, ADCT, CMPX: Current Ratio Comparison
For the Biotechnology subindustry, Monopar Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monopar Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Monopar Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monopar Therapeutics (MNPR) has a Current Ratio of 56.04 as of Mar. 2026. This is 210% above median its historical median of 18.10. Over the past decade, Monopar Therapeutics' Current Ratio has ranged from 4.08 to 56.09. According to the industry distribution chart, Monopar Therapeutics ranks #18 out of 1417 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Monopar Therapeutics' Current Ratio too high?
Monopar Therapeutics' current Current Ratio of 56.04 is 210% above median its 10-year median of 18.10. Over the past 10 years, this metric has ranged from a low of 4.08 to a high of 56.09. The Biotechnology industry median Current Ratio is 3.89. Monopar Therapeutics' value of 56.04 is 1340.6% above this industry median. Based on the distribution chart, Monopar Therapeutics ranks #18 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Current Ratio compare to IPSC and ADCT?
According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #18 out of 1417 companies for Current Ratio. This places Monopar Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Monopar Therapeutics' value of 56.04 is 1340.6% above this benchmark. Historically, Monopar Therapeutics' own Current Ratio has ranged from 4.08 to 56.09 over the past decade. While the company's 10-year median is 18.10 vs. the industry median of 3.89, Monopar Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monopar Therapeutics's current Current Ratio of 56.04 is 1340.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monopar Therapeutics's current Current Ratio is 56.04, which is 210% above median its own 10-year median of 18.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Current Ratio of 56.04. The current Current Ratio is 56.04, which is 210% above median its 10-year median of 18.10 and 1340.6% above the Biotechnology industry median of 3.89. Monopar Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Current Ratio is 56.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score
Get the complete analysis for MNPR
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNPR has been successfully added to your 
